Lineage relationship of gleason patterns in gleason score 7 prostate cancer

Cancer Research

Volumn 73, Issue 11, 2013, Pages 3275-3284

  Kovtun, Irina V ^a   Cheville, John C ^a   Murphy, Stephen J ^a   Johnson, Sarah H ^a   Zarei, Shabnam ^a   Kosari, Farhad ^a   Sukov, William R ^a   Karnes, R Jeffrey ^a   Vasmatzis, George ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; HISTONE H3; IMMUNOGLOBULIN KAPPA CHAIN; PHOSPHODIESTERASE IV; TRANSCRIPTION FACTOR SP3;

ARTICLE; BINDING SITE; CARCINOGENESIS; CELL POPULATION; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DNA SEQUENCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; GENE MAPPING; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC PROCEDURES; GLEASON SCORE; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; MALE; MOLECULAR DYNAMICS; NEXT GENERATION SEQUENCING; PHYLOGENY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DENATURATION; PROTEIN LOCALIZATION;

CELL LINEAGE; CHROMOSOME BREAKPOINTS; DISEASE PROGRESSION; DNA, NEOPLASM; GENE REARRANGEMENT; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LASER CAPTURE MICRODISSECTION; MALE; NEOPLASM GRADING; PROSTATIC NEOPLASMS;

EID: 84878571408     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2803     Document Type: Article

References (40)

1. Greene DR, Wheeler TM, Egawa S, Weaver RP, Scardino PT. Relationship between clinical stage and histological zone of origin in early prostate cancer: morphometric analysis. Br J Urol 1991;68:499-509.
2. Cheng L, Song SY, Pretlow TG, Abdul-Karim FW, Kung HJ, Dawson DV, et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst 1998;90:233-37.
3. FitzGerald LM, Agalliu I, Johnson K, Miller MA, Kwon EM, Hurtado-Coll A, et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer 2008;8:230.
4. Demichelis F, Fall K, Perner S, Andrén O, Schmidt F, Setlur SR, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26:4596-99.
5. Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 2009;56:275-86.
6. Karnes RJ, Cheville JC, Ida CM, Sebo TJ, Nair AA, Tang H, et al. The ability of biomarkers to predict systemic progression inmen with highrisk prostate cancer treated surgically is dependent on ERG status. Cancer Res 2010;70:8994-9002.
7. Yoshimoto M, Cunha IW, Coudry RA, Fonseca FP, Torres CH, Soares FA, et al. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007;97:678-85.
8. Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, et al. Molecular characterisation ofERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 2010;102:678-84.
9. Verhagen PC, van Duijn PW, Hermans KG, Looijenga LH, van Gurp RJ, Stoop H, et al. The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol 2006;208: 699-707.
10. Reid AH, Attard G, Brewer D, Miranda S, Riisnaes R, Clark J, et al. Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. Mod Pathol 2012;25:902-10.
11. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
12. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, et al. The genomic complexity of primary human prostate cancer. Nature 2011;470:214-20.
13. Bailar JC III, Mellinger GT, Gleason DF. Survival rates of patients with prostatic cancer, tumor stage, and differentiation -preliminary report. Cancer Chemother Rep 1966;3:129-36.
14. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep 1966;3:125-8.
15. Freedland SJ. Screening, risk assessment, and the approach to therapy in patients with prostate cancer. Cancer 2011;117:1123-35.
16. Albertsen PC. Treatment of localized prostate cancer: when is active surveillance appropriate? Nat Rev Clin Oncol 2010;7:394-400.
17. Bastacky SI, Wojno KJ, Walsh PC, Carmichael MJ, Epstein JI. Pathological features of hereditary prostate cancer. J Urol 1995;153: 987-92.
18. Arora R, Koch MO, Eble JN, Ulbright TM, Li L, Cheng L. Heterogeneity of Gleason grade in multifocal adenocarcinomaof the prostate. Cancer 2004;100:2362-66.
19. Andreoiu M, Cheng L. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol 2010;41:781-93.
20. Barry M, Perner S, Demichelis F, Rubin MA. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology 2007;70:630-33.
21. Guo CC, Zuo G, Cao D, Troncoso P, Czerniak BA. Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion. Mod Pathol 2009;22:866-71.
22. Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009;15:559-65.
23. Murphy S, Cheville JC, Zarei S, Johnson SH, Sikkink RA, Kosari F, et al. Mate pair sequencing of whole genome amplified DNA following laser capture microdissection of prostate cancer. DNA Res 2012;19: 395-406.
24. Feldman AL, Dogan A, Smith DI, Law ME, Ansell SM, Johnson SH, et al. Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood 2011;117:915-19.
25. Vasmatzis G, Johnson SH, Knudson RA, Ketterling RP, Braggio E, Fonseca R, et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood 2012;120:2280-89.
26. Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010;17:443-54.
27. http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc-GSE14097
28. http://genome.ucsc.edu, 2006, genome build hg18
29. Forment JV, Kaidi A, Jackson SP. Chromothripsis and cancer: causes and consequences of chromosome shattering. Nat Rev Cancer 2012;12:663-70.
30. Kloosterman WP, Tavakoli-Yaraki M, van Roosmalen MJ, van Binsbergen E, Renkens I, Duran K, et al. Constitutional chromothripsis rearrangements involve clustered double-stranded DNA breaks and nonhomologous repair mechanisms. Cell Rep 2012;1:648-55.
31. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011;144:27-40.
32. Feilotter HE, Nagai MA, Boag AH, Eng C, Mulligan LM. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 1998;16:1743-48.
33. Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 1998;58:204-9.
34. Wang SI, Parsons R, Ittmann M. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin Cancer Res 1998;4:811-15.
35. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999;59:4291-96.
36. http://www.sanger.ac.uk/genetics/CGP/Census/
37. Lin C, Yang L, Tanasa B, Hutt K, Ju BG, Ohgi K, et al. Nuclear receptorinduced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009;139:1069-83.
38. Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S, et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009;326:1230.
39. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
40. Barbieri CE, Demichelis F, Rubin MA. Molecular genetics of prostate cancer: emerging appreciation of genetic complexity. Histopathology 2012;60:187-98.